Skip to content
    Clinical Trials

    Home-Based Exercise During Chemotherapy for Gynecologic Cancers

    Kamiya et alBMC Sports Science, Medicine & Rehabilitation

    Home-Based Exercise During Chemotherapy for Gynecologic Cancers
    A randomized controlled trial evaluating a home-based exercise program during paclitaxel-carboplatin chemotherapy for gynecologic malignancies (cervical, endometrial, or ovarian cancer) demonstrated feasibility and safety, but did not show a statistically significant reduction in chemotherapy-related fatigue. A total of 110 patients were randomized 1:1 to either control care or an intervention consisting of 30 minutes of moderate-intensity walking and squats three times weekly, reinforced by triweekly rehabilitation visits for safety and technique assessment. Overall, 51 patients in the exercise group and 55 in the control group were evaluable.
    The primary endpoint of fatigue change on the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) subscale yielded a least-squares mean difference of 1.8 (95% CI: -1.3 to 4.9). High adherence was observed in the intervention group (76%), but 71% of control group participants also engaged voluntarily in comparable physical activity, representing substantial control-group contamination that likely attenuated between-group differences. Pre-existing exercise habits trended toward higher compliance (81% vs. 65%; p = 0.07).
    Despite the neutral fatigue outcome, multidimensional secondary assessments identified meaningful functional and tolerability benefits. Patients assigned to exercise demonstrated superior preservation of quadriceps muscle strength and experienced lower frequencies of grade ≥ 2 nausea and myalgia. Longitudinal CT imaging showed loss of psoas muscle mass and increased visceral adiposity in both study arms during chemotherapy, highlighting ongoing metabolic and body composition challenges during active systemic treatment.

    Key Takeaways

    • Home-based moderate-intensity exercise did not significantly improve fatigue compared to control during paclitaxel-carboplatin chemotherapy (FACIT-F LS mean difference: 1.8; 95% CI: -1.3 to 4.9), alongside high voluntary exercise rates among controls (71% vs. 76% in the intervention arm).
    • Patients undergoing the exercise intervention experienced better preservation of quadriceps strength and a lower incidence of grade ≥ 2 nausea and myalgia compared to standard care.
    • Computed tomography demonstrated progressive reduction in psoas muscle mass and an increase in visceral fat across both cohorts during active treatment.
    Read the original sourceBMC Sports Science, Medicine & Rehabilitation